K - BLADDER FUNCTION
Clinicians should prescribe oral antimuscarinics with dose-escalation as the first-line pharmacological treatment for patients with neurogenic lower urinary tract dysfunction in order to improve overactive bladder symptoms and neurogenic detrusor overactivity, decrease urgency urinary incontinence and lower detrusor pressures. (CUA 2019, p.166; Level A)
Oral antimuscarinics with dose-escalation are the first-line pharmacological treatment for patients with neurogenic lower urinary tract dysfunction in order to improve overactive bladder symptoms and neurogenic detrusor overactivity, decrease urgency urinary incontinence and lower detrusor pressures. (CUA 2019, p.166; Level A)
Mirabegron may be a useful alternative to antimuscarinic for individuals with symptoms of overactive bladder and neurogenic lower urinary tract dysfunction, but further evidence of urodynamic changes is needed in this population. (CUA 2019, p.167; Level B)
Alpha-blockers can be considered for the treatment of failure to empty the bladder secondary to detrusor sphincter dyssynergia; however, this is supported by weak evidence. (CAN-SCIP 2020; Level C)